AIP
IHE icon

Almanack Investment Partners’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Almanack Investment Partners’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-300
Closed -$17K – 649
2022
Q3 		$17K Buy
+300
New +$18.5K ﹤0.01% 400

Other funds holding IHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Almanack Investment Partners's IHE Position: Q4 2022 in Review

Almanack Investment Partners sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2022, closing a stake of 300 shares — an estimated $17K sold.

Almanack Investment Partners first reported a position in IHE in Q3 2022 and held it in 1 quarter. The position peaked at $17K in Q3 2022. 130 funds tracked by Wall St. Rank hold IHE as of Q4 2022.

  • Almanack Investment Partners reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 300 iShares US Pharmaceuticals ETF shares in Q4 2022, an estimated $17K.
  • Almanack Investment Partners first reported a position in iShares US Pharmaceuticals ETF in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's iShares US Pharmaceuticals ETF position peaked at $17K in Q3 2022.
  • 130 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.